GlassScriptPhysician profile
Douglas H Luttrell
NPI 1114954641
$10,529.66
in general payments reported to CMS, 2019-2025
57 companies · $1,869 in 2025
The $1,869 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,309 · 2022: $2,106 · 2023: $2,127 · 2024: $2,120 · 2025: $1,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,070 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,070.28 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,788.57 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,638.05 | 2021-2025 | |
| Pfizer INC. | $960.05 | 2021-2025 | |
| Lilly USA, LLC | $780.64 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $645.54 | 2021-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $566.27 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $340.05 | 2021-2025 | Xifaxan |
| Amarin Pharma, INC. | $256.02 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.05 | 2021-2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $203.79 | 2021-2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $202.83 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $170.65 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Dexcom, INC. | $170.23 | 2023-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $145.04 | 2022-2025 | |
| Exact Sciences Corporation | $141.13 | 2023-2025 | Cologuard Collection Kit |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Luttrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.